ENSYSCE BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $1212.73 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $2200.39.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $770.40, a 1678.80% increase from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $43.31.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1212.73 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $2200.39 10-Q · filed 2026-05-15 | |||
| 2023-12-31 | $770.40 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $770.40 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | $43.31 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $21.40 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |